Sonoma Pharmaceuticals (NASDAQ:SNOA) was downgraded by stock analysts at Maxim Group from a “buy” rating to a “hold” rating in a report released on Monday, March 5th, MarketBeat Ratings reports. They presently have a $7.00 price objective on the stock. Maxim Group’s price objective points to a potential upside of 81.82% from the stock’s current price.
Several other analysts also recently weighed in on SNOA. Benchmark started coverage on Sonoma Pharmaceuticals in a report on Thursday, December 28th. They issued a “speculative buy” rating and a $10.00 price objective for the company. Zacks Investment Research downgraded shares of Sonoma Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 5th.
Shares of Sonoma Pharmaceuticals (SNOA) opened at $3.85 on Monday. Sonoma Pharmaceuticals has a 52-week low of $3.50 and a 52-week high of $8.25. The company has a current ratio of 4.62, a quick ratio of 3.83 and a debt-to-equity ratio of 0.01.
Sonoma Pharmaceuticals (NASDAQ:SNOA) last released its quarterly earnings data on Wednesday, February 7th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.10). The firm had revenue of $4.84 million during the quarter, compared to the consensus estimate of $4.50 million. Sonoma Pharmaceuticals had a negative net margin of 70.46% and a negative return on equity of 70.95%. sell-side analysts predict that Sonoma Pharmaceuticals will post -2.86 earnings per share for the current fiscal year.
An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Deutsche Bank AG bought a new position in shares of Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 25,141 shares of the company’s stock, valued at approximately $137,000. Deutsche Bank AG owned 0.54% of Sonoma Pharmaceuticals at the end of the most recent reporting period. 13.24% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Sonoma Pharmaceuticals (SNOA) Cut to Hold at Maxim Group” was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.thelincolnianonline.com/2018/03/20/sonoma-pharmaceuticals-snoa-cut-to-hold-at-maxim-group.html.
Sonoma Pharmaceuticals Company Profile
Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.